Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 182-193 http://medscipublisher.com/index.php/cge 192 Leung R.K., and Whittaker P.A., 2005, RNA interference: from gene silencing to gene-specific therapeutics, Pharmacology and Therapeutics, 107(2): 222-239. https://doi.org/10.1016/j.pharmthera.2005.03.004 Li D., Gao C., Kuang M., Xu M., Wang B., Luo Y., Teng L., and Xie J., 2021, Nanoparticles as drug delivery systems of RNAi in cancer therapy, Molecules, 26(8): 2380. https://doi.org/10.3390/molecules26082380 Mainini F., and Eccles M.R., 2020, Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy, Molecules, 25(11): 2692. https://doi.org/10.3390/molecules25112692 Malla R., and Kamal M.A., 2021, E6 and E7 oncoproteins: potential targets of cervical cancer, Current Medicinal Chemistry, 28(39): 8163-8181. https://doi.org/10.2174/0929867327666201111145546 Miele E., Spinelli G., Miele E., Fabrizio E., Ferretti E., Tomao S., and Gulino A., 2012, Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy, International Journal of Nanomedicine, 3637-3657. https://doi.org/10.2147/IJN.S23696 Milner J., 2003, RNA interference for treating cancers caused by viral infection, Expert Opinion on Biological Therapy, 3(3): 459-467. https://doi.org/10.1517/14712598.3.3.459 Niu X.Y., Peng Z.L., Duan W.Q., Wang H., and Wang P., 2006, Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo, International Journal of Gynecologic Cancer, 16(2). https://doi.org/10.1136/ijgc-00009577-200603000-00044 Pai S., Yy L., Macaes B., Meneshian A., Hung C., and Wu T., 2006, Prospects of RNA interference therapy for cancer, Gene Therapy, 13(6): 464-477. https://doi.org/10.1038/sj.gt.3302694 Pal A., and Kundu R., 2020, Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy, Frontiers in Microbiology, 10: 3116. https://doi.org/10.3389/fmicb.2019.03116 Parashar D., Singh A., Gupta S., Sharma A., Sharma M., Roy K., Chauhan S., and Kashyap V., 2022, Emerging roles and potential applications of non-coding RNAs in cervical cancer, Genes, 13(7): 1254. https://doi.org/10.3390/genes13071254 Phalon C., Rao D.D., and Nemunaitis J., 2010, Potential use of RNA interference in cancer therapy, Expert Reviews in Molecular Medicine, 12: e26. https://doi.org/10.1017/S1462399410001584 Ravegnini G., Gorini F., Dondi G., Tesei M., Crescenzo E., Morganti A., Hrelia P., Iaco P., Angelini S., and Perrone A., 2022, Emerging Role of MicroRNAs in the therapeutic response in cervical cancer: a systematic review, Frontiers in Oncology, 12: 847974. https://doi.org/10.3389/fonc.2022.847974 Senapati D., Patra B., Kar A., Chini D., Ghosh S., Patra S., and Bhattacharya M., 2019, Promising approaches of small interfering RNAs (siRNAs) mediated cancer gene therapy, Gene, 719: 144071. https://doi.org/10.1016/j.gene.2019.144071 Sima N., Wang W., Kong D., Deng D., Xu Q., Zhou J., Xu G., Meng L., Lu Y., Wang S., and Ma D., 2008, RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53, Apoptosis, 13: 273-281. https://doi.org/10.1007/s10495-007-0163-8 Singh A., Trivedi P., and Jain N.K., 2018, Advances in siRNA delivery in cancer therapy, Artificial Cells, Nanomedicine, and Biotechnology, 46(2): 274-283. https://doi.org/10.1080/21691401.2017.1307210 Staley H., Shiraz A., Shreeve N., Bryant A., Martin‐Hirsch P., and Gajjar K., 2021, Interventions targeted at women to encourage the uptake of cervical screening, Cochrane Database of Systematic Reviews, (9). https://doi.org/10.1002/14651858.CD002834.pub3 Subhan M.A., Attia S.A., and Torchilin V.P., 2021, Advances in siRNA delivery strategies for the treatment of MDR cancer, Life Sciences, 274: 119337. https://doi.org/10.1016/j.lfs.2021.119337 Tabernero J., Shapiro G., LoRusso P., Cervantes A., Schwartz G., Weiss G., Paz-Ares L., Cho D., Infante J., Alsina M., Gounder M., Falzone R., Harrop J., White A., Toudjarska I., Bumcrot D., Meyers R., Hinkle G., Svrzikapa N., Hutabarat R., Clausen V., Cehelsky J., Nochur S., Gamba‐Vitalo C., Vaishnaw A., Sah D., Gollob J., and Burris H., 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discovery, 3(4): 406-417. https://doi.org/10.1158/2159-8290.CD-12-0429 Takeshita F., and Ochiya T., 2006, Therapeutic potential of RNA interference against cancer, Cancer Science, 97(8): 689-696. https://doi.org/10.1111/j.1349-7006.2006.00234.x Tian Z., Liang G., Cui K., Liang Y., Wang Q., Lv S., Cheng X., and Zhang L., 2021, Insight into the prospects for RNAi therapy of cancer, Frontiers in Pharmacology, 12: 644718. https://doi.org/10.3389/fphar.2021.644718 Xin Y., Huang M., Guo W., Huang Q., Zhang L., and Jiang G., 2017, Nano-based delivery of RNAi in cancer therapy, Molecular Cancer, 16: 1-9. https://doi.org/10.1186/s12943-017-0683-y Yeo-Teh N.S., Ito Y., and Jha S., 2018, High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis, International Journal of Molecular Sciences, 19(6): 1706. https://doi.org/10.3390/ijms19061706 Young S.W.S., Stenzel M., and Jia-Lin Y., 2016, Nanoparticle-siRNA: a potential cancer therapy?, Critical Reviews in Oncology/Hematology, 98: 159-169. https://doi.org/10.1016/j.critrevonc.2015.10.015
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==